Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned a consensus rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $34.44.

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Raymond James cut their target price on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Friday, June 14th. Wedbush reissued an “outperform” rating and issued a $34.00 price target (down from $36.00) on shares of Xencor in a report on Thursday, June 13th. BMO Capital Markets reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Xencor in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 target price on shares of Xencor in a report on Tuesday, August 6th.

Xencor Price Performance

Shares of XNCR opened at $16.23 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. Xencor has a fifty-two week low of $15.31 and a fifty-two week high of $26.84. The firm has a 50-day simple moving average of $19.11 and a 200-day simple moving average of $21.03. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -7.41 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. The company had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. During the same period in the previous year, the business posted ($0.37) earnings per share. The firm’s revenue was down 62.7% compared to the same quarter last year. On average, equities research analysts anticipate that Xencor will post -4.16 earnings per share for the current year.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 36,329 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the sale, the vice president now directly owns 192,319 shares in the company, valued at $3,523,284.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Xencor

A number of hedge funds have recently made changes to their positions in the stock. CWM LLC increased its holdings in shares of Xencor by 498.7% during the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,147 shares during the last quarter. Parallel Advisors LLC increased its stake in Xencor by 303.9% during the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,015 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,151 shares during the period. Quarry LP acquired a new position in shares of Xencor in the 2nd quarter valued at about $36,000. Finally, GAMMA Investing LLC grew its holdings in shares of Xencor by 153.7% during the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,316 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.